The United States Patent and Trademark Office (USPTO) just granted our patent that protects LIM21 and its uses in ocular diseases. This is an important step in our IP strategy since the USA market is one of the most important ones in the world.
Recent Posts
- A breakthrough in the battle against blindness: Limnopharma’s latest discovery
- Limnopharma named one of the 100 best startups of 2023
- Confirmation of Lim21 mechanism of action
- The Fight Against Blindness Foundation presents the winner of the FUNDALUCE 2022 Awards
- Limnopharma Participation in Biotechnology Fairs and Investment Events.